%0 Journal Article %T KEYNOTE-028: how do we use immunotherapy in small cell lung cancer? %A Pacheco, Jose M. %A Camidge, D. Ross %J Translational Lung Cancer Research %D 2017 %B 2017 %9 %! KEYNOTE-028: how do we use immunotherapy in small cell lung cancer? %K %X Recently, PD-1 axis inhibition has started to show activity in small cell lung cancer (SCLC), enough to suggest that, at last, a new treatment option for SCLC may have arrived. Nivolumab and nivolumab + ipilimumab are now both listed in the NCCN guidelines for second line or beyond therapy in SCLC, based on data from the Checkmate-032 study, although neither of these regimens has yet been approved by the FDA (1). Additionally, a small phase Ib study (KEYNOTE-028) recently published in The Journal of Clinical Oncology by Ott et al . has explored the use of pembrolizumab monotherapy in previously treated extensive stage SCLC (2). The emergence of immunotherapy as a therapeutic option in SCLC is exciting, but there is still a lot to learn about its true potential in this disease. %U https://tlcr.amegroups.org/article/view/16886 %P S84-S87 %@ 2226-4477